These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Acute rhabdomyolysis associated with troglitazone. Yokoyama M; Izumiya Y; Yoshizawa M; Usuda R Diabetes Care; 2000 Mar; 23(3):421-2. PubMed ID: 10868879 [No Abstract] [Full Text] [Related]
5. REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES. Einhorn D; Fonseca V Endocr Pract; 2016 Nov; 22(11):1343-1346. PubMed ID: 27540881 [No Abstract] [Full Text] [Related]
6. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821 [TBL] [Abstract][Full Text] [Related]
7. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Betteridge DJ; Vergès B Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239 [TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus. Odom J; Williamson B; Carter L Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427 [No Abstract] [Full Text] [Related]
9. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390 [TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes. Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974 [TBL] [Abstract][Full Text] [Related]
11. Leukopenia and thrombocytopenia caused by thiazolidinediones. Digman C; Klein AK; Pittas AG Ann Intern Med; 2005 Sep; 143(6):465-6. PubMed ID: 16172449 [No Abstract] [Full Text] [Related]
12. Treatment with pioglitazone induced significant, reversible mitral regurgitation. Dorkhan M; Dencker M; Frid A Cardiovasc Diabetol; 2008 Apr; 7():12. PubMed ID: 18445302 [TBL] [Abstract][Full Text] [Related]
13. Balancing the risks and benefits for pioglitazone in type 2 diabetes. Johnson JA; Colmers IN Diabetes Res Clin Pract; 2012 Oct; 98(1):1-2. PubMed ID: 22959125 [No Abstract] [Full Text] [Related]
14. Rosiglitazone and pioglitazone. Beware fractures. Dixit A; Pandey P BMJ; 2009 Sep; 339():b3957. PubMed ID: 19808816 [No Abstract] [Full Text] [Related]
15. Rosiglitazone or pioglitazone in type 2 diabetes? de Vries CS; Russell-Jones DL BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344 [No Abstract] [Full Text] [Related]
16. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! Hillaire-Buys D; Faillie JL; Montastruc JL; Petit P Eur J Clin Pharmacol; 2012 Dec; 68(12):1681-3. PubMed ID: 22576730 [No Abstract] [Full Text] [Related]
17. Pioglitazone and the risk of bladder cancer. Hillaire-Buys D; Faillie JL BMJ; 2012 May; 344():e3500. PubMed ID: 22653979 [No Abstract] [Full Text] [Related]